Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 3/20 | 0.71 |
| ▸ | CLK2 | P49760 | 3/20 | 0.71 |
| ▸ | MAP3K5 | Q99683 | 15/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | ITK | Q08881 | 2/20 | 0.48 |
| ▸ | MERTK | Q12866 | 2/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485629 | 0.85 | MAP3K5 (0.77) | CLK1CLK2MAP3K5RETCDK2 | |
| SCHEMBL3136633 | 0.83 | MAP3K5 (0.52) | CLK1CLK2MAP3K5RETCDK2 | |
| SCHEMBL3486676 | 0.81 | CLK2 (0.75) | CLK1CLK2MAP3K5GSK3B | |
| SCHEMBL3486343 | 0.81 | CLK1 (0.58) | CLK1CLK2MAP3K5 | |
| SCHEMBL3485541 | 0.81 | CLK2 (0.80) | CLK1CLK2MAP3K5RETCDK2 | |
| SCHEMBL3486151 | 0.81 | CLK2 (1.00) | CLK1CLK2MAP3K5MCHR1 | |
| SCHEMBL3486382 | 0.81 | MAP3K5 (0.54) | CLK1CLK2MAP3K5RETCDK2 | |
| SCHEMBL3486061 | 0.80 | MAP3K5 (0.77) | CLK1CLK2MAP3K5RETCDK2 | |
| SCHEMBL3486095 | 0.80 | CLK2 (0.73) | CLK1CLK2MAP3K5RETCDK2 | |
| Hydrochloric Acid SCHEMBL3486014 | 0.79 | CLK2 (0.72) | CLK1CLK2MAP3K5RETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100028259-A1 | USE OF ORGANIC CATION TRANSPORTERS FOR CANCER DIAGNOSIS AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009032172-A2 | PLATINUM COMPOSITIONS AS TREATMENT FOR OCT-RELATED CANCERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2007124314-A2 | USE OF ORGANIC CATION TRANSPORTERS FOR CANCER DIAGNOSIS AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | CLK1 2385/4885CLK2 2521/4885MAP3K5 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.